XML 23 R9.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Supplemental Financial Information | 3 Months Ended
--- | ---
Mar. 31, 2024
Supplemental Financial Information [Abstract] |
Supplemental Financial Information | Supplemental Financial Information Tempus agreement In November 2023, Recursion entered into a five-year agreement with Tempus Labs, Inc. (Tempus) to purchase access to their records of patient-centric multimodal oncology data and use rights for therapeutic development purposes. This data will be used to improve the training of Recursion’s artificial intelligence and machine learning models and is expected to accelerate Recursion’s drug discovery process. Recursion is making annual payments, ranging between $22.0 million and $42.0 million, up to $160.0 million in aggregate, to Tempus in cash or equity at the Company’s option. The equity value is determined by using the seven-trading day period dollar volume-weighted average price (VWAP) for Recursion Class A common stock ending on the day immediately preceding the date that is five business days prior to the payment date. Recursion is expensing the record purchases as “Research and Development” expenses in the Condensed Consolidated Statements of Operations as the records are purchased. To the extent that the Recursion payments to Tempus are greater than or less than the records purchased amount, Recursion records the applicable amount to “Other Current Assets” or “Accrued Expenses and Other Liabilities” on the Condensed Consolidated Balance Sheet, respectively. As of March 31, 2024, Recursion had recorded $16.0 million within “Other Current Assets” on the Consolidated Balance Sheet related to the Tempus agreement. Property and Equipment
| March 31, | December 31,
(in thousands) | 2024 | 2023
Lab equipment | $ | 61,247 |  | $ | 60,096 |
Leasehold improvements | 46,289 |  | 45,929 |
Office equipment | 22,356 |  | 22,126 |
Construction in progress | 5,677 |  | 3,231 |
Property and equipment, gross | 135,569 |  | 131,382 |
Less: Accumulated depreciation | (48,853) |  | (44,872) |
Property and equipment, net | $ | 86,716 |  | $ | 86,510 |
Depreciation expense on property and equipment was $4.0 million and $3.6 million during the three months ended March 31, 2024 and 2023, respectively. The Company recorded an insignificant impairment and an impairment of $1.2 million during the three months ended March 31, 2024 and 2023, respectively, related to construction projects for leasehold improvements as the Company no longer intended to use them. The impairment was recorded in “General and Administrative” in the Condensed Consolidated Statements of Operations. For the three months ended March 31, 2023, the Company initiated and completed a project to upgrade the BioHive supercomputer for $1.7 million. The supercomputer was classified as office equipment in the above table. Accrued Expenses and Other Liabilities
| March 31, | December 31,
(in thousands) | 2024 | 2023
Accrued compensation | $ | 10,055 |  | $ | 22,888 |
Accrued development expenses | 5,804 |  | 6,077 |
Accrued early discovery expenses | 2,610 |  | 2,570 |
Accrued construction | — |  | 2,439 |
Materials received not invoiced | 1,184 |  | 2,432 |
Accrued other expenses | 6,417 |  | 10,229 |
Accrued expense and other liabilities | $ | 26,070 |  | $ | 46,635 |
Notes Payable In January 2023, the Company entered into a financing agreement for borrowing $1.9 million as part of the supercomputer upgrade project. The debt will be repaid over a three-year period at a 7% interest rate. As of March 31, 2024, the outstanding balance was $616 thousand. In 2018, the Company borrowed $992 thousand, which was available as part of a lease agreement for use on tenant improvements. The note will be repaid over a 10-year period at an 8% interest rate. As of March 31, 2024, the outstanding balance was $510 thousand. Interest Income, net
| Three months ended March 31,
(in thousands) | 2024 | 2023
Interest income | $ | 4,048 |  | $ | 4,660 |
Interest expense | (20) |  | (19) |
Interest income, net | $ | 4,028 |  | $ | 4,641 |
For the three months ended March 31, 2024 and 2023, interest income primarily related to earnings on cash and cash equivalents in money market funds. Interest income was included in “Other income, net” on the Condensed Consolidated Statements of Operations.

X
- Definition Supplemental Balance Sheet And Income Statement Information + References No definition available. + Details
Name: | rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock
Namespace Prefix: | rxrx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Supplemental Financial Information + References No definition available. + Details
Name: | rxrx_SupplementalFinancialInformationAbstract
Namespace Prefix: | rxrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration